CVRx CVRX 深 沪
等待开盘 09-27 09:30:00 美东时间
7.55
+0.230
+3.14%
华盛通- 最 高7.705
- 今 开7.33
- 成交量 9.95万股
- 最 低 7.33
- 昨 收 7.32
- 总市值 1.97亿
- 52周最高 18.55
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 4.2993
- 委 比 81.64%
- 总股本 2607.26万
- 历史最高 33.135
- 量 比 0.45
- 振 幅 5.12%
- 历史最低 4.2993
- 每 手 1
- 风险率 3.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CVRx shares are trading lower after the company reported mixed Q2 financial results and narrowed its FY25 sales guidance.
CVRx shares are trading lower after the company reported mixed Q2 financial res...
08-05 23:35
Cantor Fitzgerald Reiterates Overweight on CVRx, Maintains $11 Price Target
Cantor Fitzgerald analyst Ross Osborn reiterates CVRx (NASDAQ:CVRX) with a Overweight and maintains $11 price target.
08-05 20:25
CVRx Appoints Brent Binkowski as New COO
An announcement from CVRx ( ($CVRX) ) is now available. On August 4, 2025, CVRx...
08-05 04:29
CVRx Sees Q3 Sales $13.700M-$14.700M vs $14.537M Est
CVRx (NASDAQ:CVRX) sees Q3 sales of $13.700 million-$14.700 million vs $14.537 million analyst estimate.
08-05 04:11
CVRx Narrows FY2025 Sales Guidance from $55.000M-$58.000M to $55.000M-$57.000M vs $56.086M Est
CVRx (NASDAQ:CVRX) narrows FY2025 sales outlook from $55.000 million-$58.000 million to $55.000 million-$57.000 million vs $56.086 million estimate.
08-05 04:11
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
CVRx, Inc. plans to release second quarter 2025 financial and operating results on August 4, 2025, after market close. A conference call and webcast will be held at 4:30pm ET the same day. CVRx is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, including Barostim™, the first FDA-approved therapy for heart failure.
07-21 20:30
CVRx's Barostim Implant Set for $45K Medicare Reimbursement Under Proposed Outpatient Rule
CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the
07-16 19:32
CVRx Announces Positive News on Outpatient Payment for Barostim
CVRx announced that CMS has proposed maintaining the Barostim implant procedure in APC 1580 with an approximate $45,000 payment for outpatient procedures. CMS is also seeking comments on a potential Level 6 Neurostimulator APC. This follows positive developments in reimbursement rates, including a higher MS-DRG for inpatient procedures and transitioning to Category I CPT codes for physician payments. These updates highlight the clinical value of ...
07-16 11:30
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
CVRx, Inc. announced that its management team will present at the William Blair 45th Annual Growth Stock Conference on June 4, 2025. The presentation will be held via webcast at 10:00am Central Time and will be available on the company's investor relations page. CVRx specializes in developing neuromodulation solutions for cardiovascular diseases, with its Barostim device approved by the FDA for heart failure treatment. The company is listed on NA...
05-28 20:30
